Abstract Number: PB0478
Meeting: ISTH 2020 Congress
Theme: Diagnostics and OMICs » Biomarkers of Thrombosis and Hemostasis
Background: Among prognosis biomarkers of thrombosis risk, the polymorphisms FV Leiden (FVL) and Prothrombin G20210A (F2GA) cause primary thrombophilia. Vascular stasis results from venous insufficiency and a vascular proinflammatory-state might be associated to the risk-allele D of the Angiotensin Converter Enzyme, ACE (I/D) gene. The thrombin generation assay using the Calibrated Automated Thrombogram (CAT) method is an effective predictor of thrombosis risk and might be useful in evaluating thromboprophilaxis, including novel oral anticoagulants (NOACs).
Aims: To evaluate the prognosis value of a panel of prothrombotic-inflammation markers for predicting thrombosis risk and the usefulness of the CAT assay in thromboprophilaxis.
Methods: After their consent to participate, 18 patients (12 females, 6 males; aged 15 to 66 yr) who had developed at least one thrombosis (5 arterial, 11 venous, 2 both) and were under various thromboprophilaxis schemes (NOACs, Vitamin-K antagonists, antiplatelet drugs or without anticoagulant), have been followed after their diagnosis: 1 FVL-homozygous, 3 FVL-heterozygous, 5 F2GA-heterozygous, 2 FVL/F2GA double-heterozygous, and 7 secondary thrombophilia. In all patients, we evaluated venous insufficiency, ACE genotype, thromboprophilaxis status and thrombosis-risk. To assess the latter, we collected blood by venopuncture in Sodium-citrate 0.19M tubes to obtain the PPP that was frozen at -80oC until the CAT assay was performed. The patients’ thrombograms were compared against a pool of normal plasma to establish the risk threshold of ETP at 124% of normal (Luna-Záizar et al., Thromb Res 136:1291;2015).
Results: Among the studied variables, only familial thrombosis history was significant (p=0.002). Venous insufficiency and proinflammatory risk ACE (D) were predominant (11/18 and 14/18 patients, respectively). The CAT assay defined the adequate hemostatic level or risk according to the ETP value.
Conclusions: The CAT assay showed better control in NOAC anti FXa than FIIa, and a risk value of ETP was found in 2/4 patients treated by antiplatelet therapy.
To cite this abstract in AMA style:
Jaloma-Cruz A-, Lara-Navarro I-, Ornelas-Ricardo D, Gonzalez-Moncada A-, Luna-Záizar H. Panel of Prothrombotic-inflammation Genetic Markers and Thrombin Generation Assay for Evaluation of Thromboprophilaxis and Thrombosis Risk in Thrombophilia Patients [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/panel-of-prothrombotic-inflammation-genetic-markers-and-thrombin-generation-assay-for-evaluation-of-thromboprophilaxis-and-thrombosis-risk-in-thrombophilia-patients/. Accessed March 21, 2024.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/panel-of-prothrombotic-inflammation-genetic-markers-and-thrombin-generation-assay-for-evaluation-of-thromboprophilaxis-and-thrombosis-risk-in-thrombophilia-patients/